$SHPH Green Planet Microcaps: GROUNDBREAKING CANCER TREATMENT
Article Link: https://richardacavalli.wixsite.com/greenplan...-treatment (Read Full)
Strong Data from NIH Sponsored Clinical Trial Suggests Ropidoxuridine Could be Major Advancement for Cancer Patients and Big Win for Shuttle Pharmaceuticals’ Shareholders
An estimated $7 billion was spent on Radiation Therapy (RT) in 2023 to treat cancer and is expected to increase to $11 billion in 2032 but its dosage and efficacy are capped or limited by the potential damage radiation poses to adjacent healthy tissue.
An NIH-sponsored clinical trial demonstrated that Iododoxuridine (Ropidoxuridine is prodrug) made cancer cells more sensitive to radiation and extended median survival by close to 60% but had serious obstacles for widespread use.
Shuttle Pharmaceuticals manufactured a new drug and an Orphan Drug application was approved by the FDA. Ropidoxuridine is a prodrug of iododoxuridine. After Ropidoxuridine is delivered orally, it is metabolized as iododoxuridine that overcomes these obstacles.
Shuttle Pharmaceuticals announced new financing and commenced enrollment for its Phase 2 clinical trial of Ropidoxuridine.
If current and future trial results continue to perform as they have in the past, Ropidoxuridine could become a windfall for cancer patients and for Shuttle shareholders.
Article Link: https://richardacavalli.wixsite.com/greenplan...-treatment (Read Full)
Strong Data from NIH Sponsored Clinical Trial Suggests Ropidoxuridine Could be Major Advancement for Cancer Patients and Big Win for Shuttle Pharmaceuticals’ Shareholders
An estimated $7 billion was spent on Radiation Therapy (RT) in 2023 to treat cancer and is expected to increase to $11 billion in 2032 but its dosage and efficacy are capped or limited by the potential damage radiation poses to adjacent healthy tissue.
An NIH-sponsored clinical trial demonstrated that Iododoxuridine (Ropidoxuridine is prodrug) made cancer cells more sensitive to radiation and extended median survival by close to 60% but had serious obstacles for widespread use.
Shuttle Pharmaceuticals manufactured a new drug and an Orphan Drug application was approved by the FDA. Ropidoxuridine is a prodrug of iododoxuridine. After Ropidoxuridine is delivered orally, it is metabolized as iododoxuridine that overcomes these obstacles.
Shuttle Pharmaceuticals announced new financing and commenced enrollment for its Phase 2 clinical trial of Ropidoxuridine.
If current and future trial results continue to perform as they have in the past, Ropidoxuridine could become a windfall for cancer patients and for Shuttle shareholders.
